Clinical Trials
33 trialsA Study of High-Dose Vit D Versus Standard of Care Vit D Supplementation
Wake Forest University Health Sciences
TEXT-Bone
ETOP IBCSG Partners Foundation
MAP3BSS
University Health Network, Toronto
Bone Mineral Density in Postmenopausal Women at Increased Risk of Breast Cancer And Who Are Receiving Exemestane on MAP3
Canadian Cancer Trials Group
Effect Of Whole Body Vibration Versus Weight Bearing Exercises On Osteoporosis In Breast Cancer Patients After Chemotherapy
Cairo University
COAT
Shanghai Jiao Tong University School of Medicine
Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial
Canadian Cancer Trials Group
Bone Mineral Density and Subsequent Cancer Risk
National Institutes of Health Clinical Center (CC)
Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries
GOG Foundation
Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer
Mayo Clinic
BREX
Finnish Breast Cancer Group
Changes in Knee Articular Cartilage Volume in Women on Aromatase Inhibitors
Monash University
REBBeCA II
University of Pittsburgh
Bone Health Management for Women Diagnosed With Breast Cancer
University of British Columbia
Zoledronate in Preventing Bone Loss in Postmenopausal Women Who Are Receiving Letrozole for Stage I, Stage II, or Stage IIIA Breast Cancer
Alliance for Clinical Trials in Oncology
Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer
Alliance for Clinical Trials in Oncology
Risedronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy for Primary Breast Cancer
Alliance for Clinical Trials in Oncology
Women's Health Initiative (WHI)
National Heart, Lung, and Blood Institute (NHLBI)
Pilot Study of Secondary Causes of Osteopenia/Osteoporosis in Adults With Breast and Prostate Cancer
City of Hope Medical Center
Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy
Novartis
Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer
National Cancer Institute (NCI)
RISAROS
Hospices Civils de Lyon
Letrozole With or Without Zoledronate in Treating Healthy Postmenopausal Women With High Breast Density
National Cancer Institute (NCI)
Do Aromatase Inhibitors (AIs) Decrease Intestinal Calcium Absorption?
University of Wisconsin, Madison
Bone Density and Bone Loss in Postmenopausal Women With Breast Cancer Receiving Treatment in Clinical Trial IBCSG-1-98
ETOP IBCSG Partners Foundation
Raloxifene With or Without Exercise Compared With Exercise Alone in Women Who Have Been Previously Treated for Breast Cancer
OHSU Knight Cancer Institute
Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer
Novartis
Tamoxifen to Prevent Bone Loss and Heart Disease in Premenopausal Women Receiving Chemotherapy for Stage I or Stage II Breast Cancer
Northwestern University
SABRE
AstraZeneca
Danish Osteoporosis Prevention Study
University of Aarhus
An Open Label Non-Interventional Evaluation of the Effect of Adjuvant Hormonal Treatment of Postmenopausal Women Wih Early Breast Cancer With Aromatase Inhibitors on Bone Mineral Density and Bone Fracture Rate in Daily Practice
AstraZeneca
Study of Bone Mineral Density in Postmenopausal Women After Treatment for Breast Cancer
Memorial Sloan Kettering Cancer Center
Macrobiotic Diet and Flax Seed: Effects on Estrogens, Phytoestrogens, & Fibrinolytic Factors
National Center for Complementary and Integrative Health (NCCIH)